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Background: Cholangiocarcinoma (CC) is a rare tumour with a dismal prognosis. As conventional
medical management offers minimal survival benefit, surgery currently represents the only chance of cure.
We evaluated DNA copy number (CN) alterations in CC to identify novel therapeutic targets.
Methods: DNA was extracted from 32 CC samples. Bacterial artificial chromosome (BAC) array com-
parative genomic hybridization was performed using microarray slides containing 3400 BAC clones
covering the whole human genome at distances of 1 Mb. Data were analysed within the R statistical
environment.
Results: DNA CN gains (89 regions) occurred more frequently than DNA CN losses (55 regions). Six
regions of gain were identified in all cases on chromosomes 16, 17, 19 and 22. Twenty regions were
frequently gained on chromosomes 1, 5, 7, 9, 11, 12, 16, 17, 19, 20 and 21. The BAC clones covering
ERBB2, MEK2 and PDGFB genes were gained in all cases. Regions covering MTOR, VEGFR 3, PDGFA,
RAF1, VEGFA and EGFR genes were frequently gained.
Conclusions: We identified CN gains in the region of 11 useful molecular targets. Findings of variable
gains in some regions in this and other studies support the argument for molecular stratification before
treatment for CC so that treatment can be tailored to the individual patient.
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Introduction
Cholangiocarcinoma (CC) is a relatively rare yet deadly tumour,
with an annual incidence that almost equals its yearly mortality
rate. The incidence of intrahepatic CC (ICC) has steadily
increased worldwide over recent decades from, for example, 0.11
to 1.33 per 100 000 men in England and Wales during 1971–2001.
This increase in incidence is paralleled with a concomitant rise in
mortality rates, with age-standardized mortality rates increasing
from 0.20 to 0.83 per 100 000 men in England and Wales during
the same period, a trend mirrored worldwide.1–4 Intrahepatic CC
now represents the commonest primary liver cancer among
women in the UK, and the second commonest worldwide.3
The outlook once diagnosed with CC is dismal, with an overall
5-year survival of 3%.5 However, this improves to 15–67% follow-
ing resection for ICC6–12 and to 23–62% in extrahepatic CC
(ECC).6,13–16 At present there is no proven survival benefit with
adjuvant chemotherapy following R0 resection.17–19
There is a lack of evidence for any substantial benefit of che-
motherapy in palliative treatment. A recent Phase III trial showed
This paper was presented at the International Hepato-Pancreato-Biliary
Association Annual Meeting, 18–22 April 2010, Buenos Aires,
Argentina.
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a survival benefit of 3.6 months with gemcitabine and cisplatin vs.
gemcitabine alone (median survival: 11.7 vs. 8.1 months).20
Despite this benefit with conventional chemotherapy, survival
rates are still disappointingly poor. The majority of cases are unre-
sectable: for example, a recent case series reported that 86.2%
of ICC and perihilar CC (PHCC) cases were unresectable at
presentation.21 It is well established that effective medical treat-
ment makes it possible to downstage inoperable colorectal liver
metastases and subsequently perform curative resections.22 There
is an urgent need to find new effective treatments for CC in order
to downstage inoperable cases so that curative resection can be
offered. Targeted cancer therapies used either as neoadjuvant
agents to downstage disease or in the adjuvant setting to prevent
relapse represent an attractive option in CC. There is, however, a
paucity of identified targets for known molecular agents in CC.
We have therefore utilized a genome-wide technique in order to
identify novel molecular targets in CC.
Comparative genomic hybridization (CGH) is a method of
scanning the whole genome for DNA copy number (CN) alter-
ations. This technique identifies regions of DNA gain and loss, and
is especially useful in studying tumours.23 The amplification (gain
of several DNA copies) of oncogenes and deletion of tumour
suppressor genes are hallmarks of cancer and represent a key
mechanism of tumourigenesis. Identifying CN gain of key target
genes has proven significant in cancer treatment. For example, in
breast cancer ErbB2 overexpression is caused by ERBB2 gene
amplification in >90% of cases and improved survival can be
achieved in these patients using targeted therapy (trastuzumab).24
In CGH, tumour and normal DNA are differentially labelled with
fluorescence dyes (tumour DNA Cy3, reference DNA Cy5) and are
then co-hybridized to metaphase spreads of chromosomes.
Hybridization of repetitive sequences is blocked using human
Cot-1 DNA. Reference and tumour DNA hybridize in a competi-
tive manner with their complementary sequences on the
metaphase chromosomes. The fluorescence of reference DNA and
tumour DNA binding to each chromosome are then measured
and quantified. The relative amounts of hybridized reference and
tumour DNA reflect the CN of genomic regions. A fluorescence
ratio in favour of Cy3 (tumour) reflects a CN gain, whereas a ratio
in favour of Cy5 (reference DNA) reflects a CN loss. The location
of the CN alteration is mapped to the physical location on the
chromosome.25 However, the use of metaphase spreads is techni-
cally challenging and allows the identification of CN changes at a
relatively low resolution of 5–10 Mb.26 Vast advances have been
achieved in CGH methodology over the last decade, which has
progressed from conventional metaphase CGH to array CGH,
which uses DNA microarrays instead of human metaphase chro-
mosome spreads.27 DNA fragments such as large-insert clones like
bacterial artificial chromosomes (BACs) or oligo-nucleotides,
which represent the human genome, are immobilized onto glass
slides.27–29 The advantage of array CGH is that it vastly improves
resolution from 1 Mb to 50 kb. Furthermore, it is faster and does
not require cytogenetic expertise. In this study, we used array




Tissue was obtained from the Hammersmith Biological Resource
Centre, a research tissue bank approved by the National Research
Ethics Service (NRES). In total, 40 CC samples were obtained
between 2003 and 2009. Intrahepatic, perihilar and extrahepatic
CCs were included in the study. Gallbladder and ampullary car-
cinomas were excluded. Intrahepatic CCs are located within the
liver parenchyma down to the second-order bile ducts; PHCCs
occur in the left and right hepatic ducts to the origin of the cystic
duct and ECCs may occur in the common bile duct down to, but
not including, the ampulla.30 All cases were adenocarcinoma. Age,
sex, survival and histopathological characteristics were recorded
for all cases.
DNA extraction and quality assessment
A tissue section adjacent to that used for DNA extraction was
stained with haematoxylin and eosin and the presence of tumour
epithelium was verified by a histopathologist (GS) and the diag-
nosis confirmed. A 10-mm section of formalin-fixed, paraffin-
embedded (FFPE) tissue was used for DNA extraction. The FFPE
section was macroscopically dissected to enrich for tumour cells,
deparaffinized in xylene and then ethanol, and incubated over-
night at 37 °C with sodium thiocyanate. DNA extraction was per-
formed according to the Qiagen QIAmp DNA Microkit standard
protocol (Qiagen, Inc., Valencia, CA, USA) using proteinase K
digestion. DNA was quantified using the NanoDrop spectropho-
tometer (ND-2000; Thermo Fisher Scientific, Inc., Waltham, MA,
USA). To ensure that the DNA was of the quality required for use
in array CGH experiments, a gene-specific, multiplex-size poly-
merase chain reaction (PCR) was used.31 Only cases with ampli-
fication products of 300 bp were deemed to be of sufficient
quality for array CGH analysis.
Array comparative genomic hybridization
Bacterial artificial chromosome arrays containing the Sanger
1-Mb BAC array clone set, which comprises approximately 3400
BAC clones covering the whole human genome in distances of
1 Mb, were used.28 BAC clones were spotted on amino-active glass
slides in triplicate (CodeLink; GE Healthcare Ltd, Chalfont St
Giles, UK).
For each experiment, 525 ng of tumour DNA and 525 ng of
reference DNA (Promega GmbH, Mannheim, Germany) were
labelled with Cy3-dCTP and Cy5-dCTP, respectively (Amersham
CyScribe Kit; GE Healthcare Ltd). Reference DNA was sex-
mismatched to the tumour sample to provide an internal hybrid-
ization control. Each sample was mixed with 35 ml of random
nonamer and 35 ml of reaction buffer and then incubated at 95 °C.
Following this, the samples were put on ice for 5 min, after which
28 ml dCTP labelling mix, 10.5 ml Cy3/5-dCTP and 3.5 ml Klenow
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(ExoFree) enzyme were added to the mixture, which was incu-
bated overnight at 37 °C. The labelled DNA was purified using
spin-filter columns (Microcon; Millipore Corp., Billerica, MA,
USA). The yield of labelled DNA and incorporation of fluores-
cence dye were determined using the NanoDrop spectrophotom-
eter. Test and reference DNA were combined with 50 mg cot-1
DNA (Invitrogen Corp., Carlsbad, CA, USA), 26 ml 10X blocking
agent (Agilent Technologies UK Ltd, Wokingham, UK) and 130 ml
2X hybridization buffer (Agilent Technologies UK Ltd), denatured
at 95 °C for 3 min and then pre-hybridized for 30 min at 37 °C.
Samples were hybridized for 60 h at 60 °C at a rotation speed of
20 rpm. Slides were washed at room temperature with Agilent
Oligo aCGH Wash Buffer 1 for 5 min and with Agilent Oligo
aCGH Wash Buffer 2 for 1 min and subsequently scanned at a
resolution of 5 mm using a microarray scanner (Agilent Technolo-
gies UK Ltd).
Data analysis
Fluorescence intensities were extracted using the array analysis
software maia (Institute Curie, Paris, France) and the resulting
text files imported into R.32 The log 2 ratios were normalized using
the R package manor,33 using default parameters (exclusion of
data points with a replicate deviation of >0.1 and/or a fore-
ground : background signal ratio of <3). Normalized profiles were
segmented using a circular binary segmentation (CBS; R package
DNAcopy) algorithm34 and called using the CGHcall algorithm.35
Called CN profiles were converted into CN regions using the R
package CGHregions36 and the percentage of cases within a group
showing CN alterations was determined by assessing frequency
plots of CN alterations.
ErbB2 protein expression
To verify ErbB2 CN gains identified by array CGH, ErbB2 protein
expression was assessed in a subset of 19 cases by immunohis-
tochemistry (IHC). The I-VIEW DAB Detection Kit (catalogue
no. 760-091; Ventana Medical Systems, Inc., Tucson, AZ, USA) was
used with standard dilutions using the Benchmark XT. Cases were
scored by a histopathologist (GS) using the ToGA Trial criteria for
grading gastric adenocarcinoma (+1, +2, +3).37,38
Results
Clinical data
DNA was extracted from 40 cases, 32 of which passed quality
assessment by size PCR and were analysed for CN changes by
aCGH. These included seven cases of ICC, 13 of PHCC and 12 of
ECC. Clinicopathological data for the 32 cases are listed in Table 1.
Twenty-three samples were from resection specimens and nine
were from biopsies (non-resections). All patients received chemo-
therapy, either postoperatively or after diagnosis in the non-
operative group. Mean patient age at diagnosis was 60.8 years
(range: 25–77 years). Survival data were available for all except
three cases, which were lost to follow-up at 1, 4 and 11 months,
respectively, giving an overall mean follow-up of 12.5 months
(range: 1–79 months). Overall survival from diagnosis differed
significantly between the resection and non-resection groups (23
months vs. 9 months; P = 0.009, Gehan–Breslow–Wilcoxon test).
Copy number alterations
All cases revealed CN alterations. DNA CN gains occurred more
frequently than DNA CN losses overall (Fig. 1), with 89 regions of
CN gain and 55 regions of CN loss. Six regions of gain were
identified in all cases at: 16q21→24.2; 17p13.3→q21.32;
17q22→24.1; 17q24.3→25.3; 19p13.3→13.11; 19q13.12→13.43,
and 22q11.1→13.33. A further 29 regions of gain appeared fre-
quently (in >20 cases) on chromosomes 1, 5, 7, 9, 11, 12, 16, 17, 19,
20 and 21 (Table 2), whereas CN losses were much less frequent
(Table 3). No region was lost in all cases. The overall frequency of
gains and losses was lower in the ECC group. There was no asso-
ciation of groups defined by unsupervised hierarchical clustering
with differentiation, perineural or vascular invasion.
Genes for novel potential therapeutic targets
Candidate genes were identified from the Ensembl database
(http://www.ensembl.org) and a literature search of known
amplified oncogenes in human cancers with established and
promising agents for molecular targeting.39 Several genes of inter-
est were identified within the altered regions (Table 4). The BAC
clones covering the genes ERBB2, MEK2 and PDGFB were gained
in all cases. Regions covering the genes MTOR,VEGFR 3, PDGFA,
RAF1, VEGFA and EGFR were frequently gained in 28, 23, 21, 19,
12 and 10 cases, respectively. FLT3 and MEK1 were each gained in
one case. Gain of the region covering VEGFA and EGFR did not
demonstrate a survival disadvantage.
ErbB2 protein expression
ErbB2 expression was heterogeneous throughout the tumour
tissue, with some areas showing strong expression and others in
the same tumour section showing none (Figs 2 and 3). Overall, 19
cases were positive, of which 10 were scored as +2 and one as +3.
Discussion
Recent advances in targeted cancer therapies, particularly in the
development of monoclonal antibodies (MAb) and tyrosine
kinase inhibitors (TKIs), have brought about significant changes
in oncology practice. There has been a surge in the development of
such agents, many of which have now been licensed for clinical use
in a variety of tumours, and dozens of further agents are in the
pipeline at various stages of development. Because of the disap-
pointing effectiveness of conventional chemotherapy in CC, tar-
geted cancer therapies represent an appealing potential treatment
option for this resistant tumour. To date, however, no targeted
agent has been effectively tested and licensed for clinical use for
CC. Experience gained with other tumour types suggests that
considerable heterogeneity exists amongst tumours of the same
pathological type in the same tissue. Therefore, blind treatment of
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all CCs may lead to a less efficient response in many patients when
targeted treatments are used. As experience in breast cancer using
trastuzumab has already shown, pre-screening of the patient
population to identify those who express the target can potentially
lead to the identification of those patients who will benefit most
from these expensive treatments.
This is the first UK study of CC using array CGH. We employed
a genome-wide technique assessing DNA CN alterations in 32 UK
cases of CC. We identified 89 regions of CN gain and 55 regions of
CN loss in CC. Frequent CN gains were identified on chromo-
somes 1, 5, 7, 9, 11, 12, 16, 17, 19, 20, 21 and 22. Copy number
losses were much less frequent. Eleven genes of interest in CC for
Table 1 Clinicopathological data for the 32 cases analysed in the current study
Age, years/sex Location Survival,
months





69/F ICC 43 (A) Extended right hepatectomy Moderate pT3 N1 1 No No
64/F ICC 46 (A) Left hepatectomy, excision of biliary tree Moderate pT1 N1 1 No No
58/M ICC 15 Wedge resection, RFA Moderate 2 No Yes
25/M ICC 23 Left lateral segmentectomy, RFA Poor pT2 N0 2 No No
71/F PHCC 1 (LTF) Left hepatectomy, excision of biliary tree Moderate pT2 N0 1 No Yes
53/M PHCC 12 Right hepatectomy, excision of biliary tree Poor pT2 N1 0 No Yes
67/M PHCC 48 Right hepatectomy, excision of biliary tree Good–moderate pT2 N0 0 No No
76/F PHCC 8 Right hepatectomy Moderate pT2 Nx 1 No No
69/M PHCC 1 Left hepatectomy Moderate pT2 N0 1 No No
60/M PHCC 11 (A) Right hepatectomy, excision of biliary tree Moderate–poor pT3 N1 1 No Yes
57/M PHCC 13 Extended right hepatectomy, excision of
biliary tree
Poor pT3 N1 1 No Yes
73/M PHCC 7 (A) Extended right hepatectomy Moderate pT3 N1 1 No No
39/F PHCC 14 (A) Left hepatectomy, RFA 2 No No
72/M ECC 10 Excision of biliary tree Moderate–poor pT2 N1 1 Yes Yes
46/M ECC 20 (A) Pylorus-preserving
pancreaticoduodenectomy
Poor pT3 N1 0 Yes Yes
77/M ECC 10 Excision of biliary tree Poor pT2 N0 1 No No
57/M ECC 37 (A) Excision of biliary tree Moderate–poor pT3 Nx 2 Yes Yes
67/F ECC 27 Excision of biliary tree, distal gastrectomy Good–moderate pT4 N0 2 No No
68/M ECC 22 Pylorus-preserving
pancreaticoduodenectomy
Well pT3 N0 2 No No
63/M ECC 26 Excision of biliary tree pT1 N0 1 No Yes
73/M ECC 12 Excision of biliary tree pT3 N0 0 No Yes
56/M ECC 25 Excision of biliary tree Moderate pT3 N1 1 Yes Yes
52/M ECC 11 (LTF) Excision of biliary tree Moderate–poor pT2 N1 1 No Yes
Non-resection group
38/M ICC 4 (LTF) Laparotomy, RFA (segments II, III, IV, V),
tumour biopsy, absolute alcohol injection
to segment V liver lesion
Poor – – – –
68/F ICC 1 Biopsy – – – – –
60/M ICC 25 Biopsy – – – – –
72/F PHCC 2 Biopsy Poor – – No No
57/F PHCC 79 Palliative bypass Poor – – – –
73/M PHCC 3 Biopsy – – – No No
47/M PHCC 9 Biopsy – – – – Yes
62/M ECC 10 Biopsy – – – – –
56/M ECC 14 Palliative bypass Moderate – – – –
M, male; F, female; ICC, intrahepatic cholangiocarcinoma; ECC, extrahepatic cholangiocarcinoma; PHCC, perhilar cholangiocarcinoma; A, alive; RFA,
radiofrequency ablation; LTF, lost to follow-up
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targeted cancer therapies with proven efficacy in other cancers
were identified (Tables 4 and 5). At present, targeted agents in CC
have been trialled at Phase I/II, apart from cediranib, for which a
Phase II/III trial has recently started recruitment.
Studies of CC to date have shown widely variable expression
profiles for many molecular targets in CC. The region encoding
ERBB2 at 17q12 was gained in all cases of CC in our study. In
breast cancer, there are high levels of concordance (97%)
between ErbB2 gain identified by array CGH and protein over-
expression.40 There is also a well-established scoring system for
protein overexpression demonstrated by IHC in breast cancer,
which is related to predicted treatment response to trastuzumab.
Data from the ToGA Trial in gastric cancer, however, demon-
strated that the standard breast cancer scoring system was insuf-
ficient for gastric malignancies because of the difference in
heterogeneity between gastric cancer and breast tumours.37,38
Thus, a gastric cancer scoring system was proposed and vali-
dated by a consensus panel to allow for incomplete staining and
tissue heterogeneity. The gastric cancer scoring system allots
scores of +2 and +3 for weak to moderate, and moderate to
strong, complete or basolateral staining in >10% of tumour cells,
respectively. Cholangiocarcinomas, like gastric cancers, are het-
erogeneous tumours with prolific stromal components and
therefore the gastric cancer scoring system was adopted for this
study. Surprisingly, although ErbB2 was gained in all our
cases, this only translated to 58% (11/19) of cases with +2/+3
IHC positivity. Interestingly, some areas of tumour demon-
strated strong ErbB2 staining, whereas other areas within the
same tumour were negative. This suggests that the standard
breast cancer scoring system for ErbB2 IHC would be inad-
equate for assessing those likely to benefit from trastuzumab
therapy, and the gastric cancer system may be significantly
better. Further studies are required to validate this. It also sug-
gests that, although ErbB2 was gained at a DNA level in all cases
in this study, there is a further level of control of expression at a
transcriptomic or proteomic level. Our findings are supported
by the widely variable data from other studies of ErbB2 in
CC, in which gene amplification is reported in 2–100% of
cases41–45 and protein overexpression varies from none to
80%.41–58 Other CGH studies using metaphase chromosome
CGH have identified CN gain in the same region in only 0–50%
of cases (Fig. 4).
To date, there have been several CGH studies of CC, but only six
have published regions of CN alteration (Table 6).59–66 These
studies used metaphase chromosome CGH, a less robust technique
with reduced resolution, to report gained and lost chromosomal
regions. As the chromosomal locations of each of the altered genes
reported in this study are known, the altered gene regions can be
compared between studies for each target (Fig. 4). Previous CGH
studies of CC have been performed in a variety of different popu-
Figure 1 DNA copy number (CN) alterations in all cases showing regions of gain and loss
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lations, including in Germany, the USA, South Korea and Japan.
Differing aetiological factors may have contributed to the different
CN profiles observed. For example, in eastern Asia (China, Korea,
Thailand, Vietnam, Laos and Cambodia) liver flukes are endemic:
approximately 1.8 million people are infected with Clonorchis sin-
ensis in Korea67 and 36.4% of the population are infected with
Opisthorchis viverrini in northeast Thailand.68 Liver fluke infection
accounts for the high rates of CC in eastern Asia: for example, in
Khon Kaen, Thailand, the age-standardized incidence rate of
primary liver cancer in men is 90.0 per 100 000 person-years and
89% of cases are CC.69 However, outside eastern Asia, liver flukes
are rare and other aetiological factors play key roles. In Japan, 9% of
cases are associated with hepatolithiasis, which is a rare phenom-
enon in Western countries.70 Furthermore, gene expression profiles
of CC associated with liver fluke in Thailand and CC not associated
with liver fluke in Japan revealed distinct differences in gene expres-
sion, with Thai CC associated with the upregulation of genes
involved in the xenobiotic metabolism, and Japanese CC associated
with the upregulation of genes related to growth factor signalling.71
In the USA and Europe, obesity is a recognized risk factor for CC.72
Table 2 Regions with frequent copy number gain
Chromosome Chromosomal regions Clones, n Cases, n
1 p13.3→p21 53 28
1 q21.1→21.3 11 24
1 q31.3→32.1 8 23
5 q34→35.3 14 23
7 p22.1→22.3 10 21
7 q11.21→11.22 9 23
7 q11.23 4 25
7 q22.1 7 26
9 q33.3→34.3 16 30
11 q12.2→13.4 19 30
11 q23.1→25 30 22
12 p13.31→13.33 12 20
12 q13.11→13.2 15 30
12 q23.3→24.23 12 28
12 q24.23→24.33 18 29
16 p13.3→11.2 34 31
16 q21→24.2 32 32
17 p13.3→q21.32 71 32
17 q22→24.1 15 32
17 q24.2→24.3 4 29
17 q24.3→25.3 13 32
19 p13.3→13.11 24 32
19 q13.11→13.12 4 26
19 q13.12→13.43 32 32
20 q11.21→11.23 14 27
20 q11.23→12 5 20
20 q13.11→13.33 32 27
21 q22.2→22.3 4 20
22 q11.1→13.33 53 32
Table 3 Regions with frequent copy number loss
Chromosome Chromosomal regions Clones, n Cases, n
1 q25.3→35.2 14 22
6 p12.3 4 20
6 p25.3→12.1 4 23
6 p12.1→q16.3 47 25
6 q21→25.2 51 21
17 q21.3→22 4 22
Table 4 Genes of interest identified within the altered regions




MEK2 (MAP2K2) 19p13.3 32




VEGFR 3 (FLT4, PCL) 5q34–q35 23
PDGFA (PDGF1) 7p22.3 21
RAF1 (c-Raf ) 3p25.1 19
VEGFA (VPF) 6p12 12
EGFR (ERBB1) 7p12 10
FLT3 (CD135, STK1, FLK2) 13q12.2 1
MEK1 (MAP2K1, MAPKK1) 15q22.1–q22.33 1
Figure 2 ErbB2 expression using immunohistochemistry
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Overall, 68% of the adult population in the USA and Europe is
overweight or obese, and almost 26% and 24% of women are obese
in the USA and the UK, respectively.73,74 In comparison, the inci-
dence of obesity in eastern Asia is low. The worldwide variation in
risk factors for CC may explain the genetic variability of CN target
gains between studies and strengthens the need for molecular
stratification before treatment.
Several small Phase II trials have been performed in CC with
targeted cancer therapy; however, to date, their outcomes have
been disappointing. Lapatinib is an orally administered agent that
targets EGFR and ErbB2 tyrosine kinases. It is licensed in the UK
for the treatment of breast cancer in combination with capecitab-
ine.75 A Phase II trial involving 17 patients with biliary tree cancers
demonstrated poor results, with a median progression-free sur-
vival of 1.8 months, overall survival of 5.2 months, and no objec-
tive responses when using lapatinib as a single agent.76 EGFR
expression was measured in only two cases (both positive), but
ErbB2 expression was not measured. We found that ERBB2 was
gained in all our cases and EGFR was gained in 10 cases (31%). It
is possible that EGFR and/or ERBB2 were not overexpressed in the
majority of cases in the trial population, which would account for
the poor outcome in the trial.
Erlotinib is an EGFR TKI licensed for the treatment of pancre-
atic and non-small cell lung cancer in combination with conven-
tional chemotherapy. The first Phase II trial treating CC patients
with erlotinib was published in 2006.77 Forty-two patients were
treated daily with erlotinib monotherapy. The median time to
disease progression was 2.4 months and median overall survival
was 7.5 months. Overexpression of EGFR was assessed by IHC in
36 patients, for 81% of whom findings were positive (1+ to 3+).
EGFR status did not correlate significantly with clinical outcome.
Our study failed to demonstrate a correlation between EFGR gain
and survival.
Bevacizumab is an i.v. administered MAb that inhibits vascular
endothelial growth factor-A (VEFG-A). In the UK it is licensed for
the treatment of colorectal cancer, breast cancer, renal cell carci-
noma and non-small cell lung cancer in combination with con-
ventional chemotherapy. A recently completed single-arm Phase
II trial treating 35 CC patients with gemcitabine, oxaliplatin and
bevacizumab has shown promising results.78 Median progression-
free survival was 7 months, overall survival was 12.7 months and
the objective response rate was 40%. There are currently four
further Phase II studies investigating the effect of bevacizumab
on patients with CC. A more recent multicentre Phase II trial
recruited 53 patients for treatment with erlotinib and bevaci-
zumab.79 Median overall survival was 9.9 months and median
time to disease progression was 4.4 months. This trial investigated
EGFR mutation and serum VEGF; serum levels in 26 patients had
no significant relation to outcome. VEGFA was gained in 12 cases
(38%) in our study, and bevacizumab appears to be a promising
agent in combination with conventional chemotherapeutic agents
for these cases.
Cediranib (Recentin, AZD2171) is an orally administered TKI
targeting all three VEGFRs (VEGFR-1, -2 and -3), cKIT, PDGFRA
and PDGFRB.80 The ABC-03 Trial is a randomized Phase II/III
trial designed to compare cediranib or placebo in combination
with cisplatin/gemcitabine in subjects with advanced biliary tract
cancers.81 It is currently recruiting patients. Our data show that a
high percentage of CC patients exhibited gains in regions encod-
ing for VEGFR2, VEGFR3, PDGFA and PDGFB. In this setting,
cediranib may represent a potentially effective agent. In reference
to the CN profiles identified in our study, cediranib represents an
appealing potential treatment option.
The diverging incidences of ICC and ECC suggest possible
differences in the molecular pathogenesis of CC at different ana-
tomical sites and, consequently, expression of different molecular
targets. Fewer gains and considerably fewer losses were observed
in ECC compared with ICC and PHCC. However, these differ-
ences were not statistically significant enough to be used as a tool
for pre-screening the population prior to targeted therapy based
on anatomical subtypes. A recent prospective, multicentre pilot
study included 66 patients with a variety of malignant diseases
refractory to treatment, who underwent molecular stratification
by IHC, fluorescence in situ hybridization (FISH) and limited
gene expression profiling (51 genes) for molecular targets with
established targeted agents.82 Treatment was chosen based on the
individual’s expression of molecular targets and compared with
progression-free survival on his or her previous regime. Eighteen
of 66 patients showed improvements in progression-free survival
following molecular profiling-driven treatment choices (9.7 vs.
5.0 months), which suggests a promising method for molecular
stratification of CC patients.
Cholangiocarcinoma remains a challenging malignancy to
treat. We have identified 11 targets, eight of which were variably
Figure 3 ErbB2 expression using immunohistochemistry
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Figure 4 Copy number (CN) gain of molecular targets in other comparative genomic hybridization studies
Table 5 Therapies currently licensed or in trial in other malignancies relevant to the targets identified in this study
Agent Alternative names Target Licensed Tumours
ARRY-438162 MEK 162 MEK (1/2) inhibitor Phase I Multiple ST
Bevacizumab Avastin VEGFA Yes CRC
Cediranib Recentin, AZD2171 Pan VEGFR TK, PDGFB, cKIT Phase III CRC
Cetuximab Erbitux EGFR Yes CRC
Erlotinib Tarceva EGFR TK Yes Pancreatic
Everolimus RAD001, Afinitor MTOR Yes RCC
Lapatinib Tyverb EGFR and ERBB2 TKs Yes Breast
Lonafarnib SCH66336, Sarasar Farnesyl-OH-transferase inhibitor interferes with the RAS/RAF/MAPK
pathway. Targets the level of H-Ras; does not inhibit the functional
activity of K-Ras and N-Ras
Phase III NSCLC
Panitumumab ABX-EGF, Vectibix EGFR Yes CRC
Sorafenib Nexavar, BAY 43-9006 RAF/MEK/ERK pathway at the level of Raf kinase, VEGFR-2, VEGFR-3
and PDGFR-b
Yes RCC
Sunitinib Sutent, SU11248 Multiple receptor TKVEGFR-1, VEGFR-2, FLT3, cKIT, PDGFR-a Yes RCC, GIST
Trastazumab Herceptin ERBB2 Yes Breast
Vandetanib Zactima, ZD6474 TK vs.VEGFR-2, EGFR and RET Phase III NSCLS
TK, tyrosine kinase; CRC, colorectal cancer; ST, solid tumour; RCC, renal cell carcinoma; NSCLC, non-small cell lung cancer; GIST, gastrointestinal
stromal tumour
Table 6 Comparative genomic hybridization studies reporting regions of copy number alterations in cholangiocarcinoma
Study Year Cases, n CC type Country Technique
Homayounfar et al.59 2009 22 22 ICC Germany Metaphase CGH
Rijken et al.60 1999 14 14 ECC USA Metaphase CGH
Koo et al.61 2001 11 11 ICC South Korea Metaphase CGH
Lee et al.62 2004 33 33 ICC South Korea Metaphase CGH
Uhm et al.63 2005 19 19 ICC South Korea Metaphase CGH
Shiraishi et al.64a 2001 50 8 ICC, 9 PHCC, 16 ECC, 17 GB Japan Metaphase CGH
aData from two previous studies by Shiraishi65,66 are included in this study
CC, cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; ECC, extrahepatic cholangiocarcinoma; PHCC, perhilar cholangiocarcinoma; GB,
gallbladder carcinoma; CGH, comparative genomic hybridization
316 HPB
HPB 2011, 13, 309–319 © 2011 International Hepato-Pancreato-Biliary Association
gained. The variable gain of molecular targets in this and other
studies supports the argument for molecular stratification before
treatment for this complex malignancy. Molecular stratification
enables treatment to be tailored to the individual patient with
the aim of improving outcome. A multitude of regimes compris-
ing conventional and/or targeted agents have and are being tri-
alled. Monotherapy with targeted agents has yielded disap-
pointing results to date and there is an urgent need to investigate
targeted agents used in combination therapy with conventional
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